美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Kailera Therapeutics, Inc.

11.12

-0.4900-4.22%

成交量：4.59万

成交额：51.94万

市值：14.40亿

市盈率：-4.93

高：11.39

开：11.39

低：11.08

收：11.61

52周最高：28.23

52周最低：9.76

股本：1.30亿

流通股本：4,492.19万

量比：5.55

换手率：0.10%

股息：- -

股息率：- -

每股收益(TTM):-2.2543

每股收益(LYR):-7,819.9811

净资产收益率：-36.90%

总资产收益率：-22.73%

市净率：1.29

市盈率(LYR):0.00

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Kailera Therapeutics宣布Kainetic全球III期临床项目完成受试者入组，评估GLP-1/GIP受体双重激动剂Ribupatide注射液

数据简报-随着竞争日趋激烈，减肥药开发商纷纷抢占这一利润丰厚的市场

Kailera Therapeutics旗下高剂量Ribupatide注射剂2b期临床试验完成全部入组；数据预计2027年中出炉

Kailera Therapeutics 向FDA提交Ribupatide口服活性IND申请，计划2027年上半年启动三期肥胖症临床试验

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/KLRA"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics, Inc.","latestPrice":11.12,"timestamp":1791811909480,"preClose":11.61,"halted":0,"volume":45900,"delay":0,"changeRate":-0.04220499569336781,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"交易中","change":-0.49,"latestTime":"10-12 09:31:50 EDT","open":11.39,"high":11.39,"low":11.084,"amount":519372.68309999997,"amplitude":0.026357,"askPrice":11.17,"askSize":1,"bidPrice":11,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":11.61,"preHourTrading":{"tag":"盘前","latestPrice":11.4898,"preClose":11.61,"latestTime":"09:26 EDT","volume":3173,"amount":37065.726319,"timestamp":1791811615010,"change":-0.1202,"changeRate":-0.010353,"amplitude":0.025736},"postHourTrading":{"tag":"盘后","latestPrice":11.54,"preClose":11.61,"latestTime":"19:49 EDT","volume":40356,"amount":468730.5049,"timestamp":1791589772631,"change":-0.07,"changeRate":-0.006029,"amplitude":0.022394},"volumeRatio":5.545404,"impliedVol":0.7988,"impliedVolPercentile":0.5714},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":5.545404,"shares":129537300,"dividePrice":0,"high":11.39,"amplitude":0.026357,"preClose":11.61,"low":11.084,"week52Low":9.76,"pbRate":"1.29","week52High":28.2271,"institutionHeld":0,"latestPrice":11.12,"eps":-2.254252,"divideRate":0,"volume":45900,"delay":0,"ttmEps":-2.254252,"open":11.39,"prevYearClose":16,"prevWeekClose":11.61,"prevMonthClose":11.42,"prevQuarterClose":11.42,"fiveDayClose":10.84,"twentyDayClose":13.75,"sixtyDayClose":18.55,"earningDate":1793721600000,"earningTime":"盘后"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"date":"2026-11-04","symbol":"KLRA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1793826000000,"name":null,"time":"盘后","dateTimestamp":1793768400000,"actualEps":null},{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"盘后","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783483200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-10-09","current":-4.9329,"percent":1,"low":-21.871461,"twenty":-18.692055,"median":-11.897285,"eighty":-7.064366,"high":-4.436859,"avg":-12.839091,"sd":5.511911,"marketCap":1296436760},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-28","current":-8.221499,"twenty":-19.532674,"median":-16.131833,"eighty":-11.014222,"marketCap":2402297316},{"date":"2026-09-04","current":-6.983615,"twenty":-19.497291,"median":-13.667441,"eighty":-10.594351,"marketCap":2040591460},{"date":"2026-09-11","current":-6.615356,"twenty":-19.448642,"median":-13.506901,"eighty":-10.353542,"marketCap":1932987209},{"date":"2026-09-18","current":-5.732421,"twenty":-19.325153,"median":-12.9728,"eighty":-8.138973,"marketCap":1674996293},{"date":"2026-09-25","current":-5.315357,"twenty":-18.99469,"median":-12.812261,"eighty":-7.882523,"marketCap":1553131238},{"date":"2026-10-02","current":-4.893855,"twenty":-18.745973,"median":-12.669466,"eighty":-7.29952,"marketCap":1429969746},{"date":"2026-10-09","current":-4.436859,"twenty":-18.692055,"median":-11.897285,"eighty":-7.064366,"marketCap":1296436760}],"updateTime":1791811910177},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1108768619","title":"Kailera Therapeutics宣布Kainetic全球III期临床项目完成受试者入组，评估GLP-1/GIP受体双重激动剂Ribupatide注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=1108768619","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108768619?lang=zh_cn&edition=fundamental","pubTime":"2026-09-30 19:02","pubTimestamp":1790766130,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics, Inc.近日宣布，其Kainetic全球III期临床项目已完成全部受试者入组。该项目旨在评估GLP-1/GIP受体双重激动剂Ribupatide注射液的安全性与有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142742","title":"数据简报-随着竞争日趋激烈，减肥药开发商纷纷抢占这一利润丰厚的市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142742","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142742?lang=zh_cn&edition=fundamental","pubTime":"2026-09-22 21:09","pubTimestamp":1790082578,"startTime":"0","endTime":"0","summary":"数据简报-随着竞争日趋激烈，减肥药开发商纷纷抢占这一利润丰厚的市场更新发稿日期，补充罗氏和Viking Therapeutics提供的最新减肥药临床试验数据路透9月22日-减肥药市场正蓬勃发展，生物技术公司竞相争夺这一由诺和诺德和礼来主导的快速增长领域的市场份额。在其中一项试验中，该药物帮助超重患者减重22.7%，低于诺和诺德25%的预期。辉瑞表示，其目标是在2028年获得快速增长的减肥药市场中的首次批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4S45E0UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXH","03692","KURE","BBH","ALT","WDNA","02105","FHLC","AMGN","01093","SUHJY","VKTX","SRRK","LLYZ","MTSR","03145","IXJ","OPK","OZEM","MEDX","HRTS","80016","LLYX","VHT","PPH","BIB","PAWZ","TRUH","KLRA","IBB","LLII","TBXU","GPCR","CURE","IBRN","CANC","IBBQ","03121","GDOC","JDOC","THNR","00016","AGNG","LLY","PFE","03933","AZN.UK","MRK","PBE","ELIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180540299","title":"Kailera Therapeutics旗下高剂量Ribupatide注射剂2b期临床试验完成全部入组；数据预计2027年中出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=1180540299","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180540299?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 04:45","pubTimestamp":1786567521,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics（股票代码：KLRA，公司全称：Kailera Therapeutics, Inc.）近日宣布，其正在进行的高剂量Ribupatide注射剂2b期临床试验已完成全部患者入组工作。这一里程碑标志着该研究迈入关键阶段。根据公司规划，相关试验数据预计将在2027年年中正式发布。Ribupatide作为一款备受关注的注射剂候选药物，此次高剂量方案的研究结果将为其后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","BK4139","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198856529","title":"Kailera Therapeutics 向FDA提交Ribupatide口服活性IND申请，计划2027年上半年启动三期肥胖症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1198856529","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198856529?lang=zh_cn&edition=fundamental","pubTime":"2026-08-13 04:44","pubTimestamp":1786567448,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics 公司已正式向美国食品药品监督管理局（FDA）提交了关于Ribupatide口服活性成分的研究性新药（IND）申请。与此同时，该公司规划在2027年上半年，启动针对肥胖症的三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA","OZEM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":20,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/KLRA\",params:#limit:6,delay:false,,,undefined,":[]}}